Related Experiment Video
Updated: Aug 25, 2026

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Place of OTC analgesics and NSAIDs in osteoarthritis
1Department of Pharmacology, Université Victor Segalen, 33076 Bordeaux, France. nicholas.moore@pharmaco.u-bordeaux2.fr
Abstract:
The risk related to the use of non-steroid anti-inflammatory drugs (NSAIDs) depends on the dose and duration of their use, in addition to the nature of the drug, and patient characteristics. The measures of risk and recent promotion of safer drugs have been mostly based on the results of clinical trials using continuous full-dose use of NSAIDs for periods up to 12 months which may not reflect real-life use and risks of the drugs. To assess this we did two studies of the utilisation of NSAIDs, one in a claims database to measure the amount of drugs dispensed to OA patients over 9 months, which showed that only a small fraction of patients actually bought enough analgesics or NSAIDs to cover the whole study period. On average, patients bought enough NSAIDs to cover 60 of 270 days. The second study was a survey of General Practitioners and rheumatologists to assess the number of users of NSAIDs seen over 2 days' consultations, the indications for and patterns of NSAIDs use. 11% of GP patients and 26% of rheumatologists' patients used NSAIDs, one-third for osteoarthritis (OA), about 8-10% for rheumatoid arthritis (RA) and the rest for various painful conditions. In OA and other conditions patients, more than 70% of patients had been taking their NSAIDs for less than 15 days at the time of consultation, whereas 42% of RA patients had been taking them for more than 6 months.
Insights
Real-world non-steroidal anti-inflammatory drug (NSAID) use is often intermittent, not continuous. This study reveals that many patients use NSAIDs for short durations, challenging assumptions from clinical trials.
Area of Science:
- Pharmacology
- Rheumatology
- Public Health
Background:
- Non-steroidal anti-inflammatory drug (NSAID) risks are dose- and duration-dependent, influenced by drug type and patient factors.
- Clinical trial data on NSAID risks may not reflect real-world usage patterns, which can be intermittent rather than continuous.
- Understanding actual NSAID utilization is crucial for accurate risk assessment and patient management.
Purpose of the Study:
- To evaluate the real-world utilization patterns of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with osteoarthritis (OA) and other painful conditions.
- To compare NSAID dispensing data with physician-reported usage patterns in general practice and rheumatology settings.
- To assess the duration and frequency of NSAID use in various patient populations.
Main Methods:
- A claims database analysis tracked NSAID dispensing to osteoarthritis (OA) patients over nine months.
- A survey of General Practitioners (GPs) and rheumatologists assessed NSAID use in patients during two-day consultations.
- Data collected included indications for NSAID use and duration of treatment.
Main Results:
- Claims data indicated patients purchased NSAIDs for an average of 60 out of 270 days.
- NSAID use was reported in 11% of GP patients and 26% of rheumatology patients.
- In OA and other conditions, over 70% of patients used NSAIDs for less than 15 days; however, 42% of rheumatoid arthritis (RA) patients used them for over six months.
Conclusions:
- Real-world NSAID use, particularly for OA, is often characterized by intermittent, short-term prescriptions, differing from continuous use in many clinical trials.
- Duration of NSAID use varies significantly by condition, with rheumatoid arthritis (RA) patients demonstrating longer-term usage.
- These findings highlight the need to consider diverse NSAID usage patterns when evaluating drug safety and efficacy in clinical practice.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Nociception
Drug Classes and Categories